Floatz logo

Enitociclib

High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement

Vincerx Pharma, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
University of Washington
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Enitociclib is also rated in:

NHLDormant
CCC
Indicative ·
51 / 100
View asset →
lymphoid neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →